anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain an insulin analog formulation stable for a long period and suitable for commercial use. SOLUTION: This formulation is a parenteral pharmaceutical preparation which comprises a soluble phase containing a monomeric insulin analog having a super-rapid time-action profile and insulin-NPH crystal which contains 0.25-0.30 mg protamine per 100 U insulin; wherein the soluble phase contains insulin at &lt;20% (pref. &lt;10%) relative to the concentration of the total soluble proteins. The monomeric insulin analog is esp. pref. LysB&lt;28&gt; ProB&lt;29&gt; -human insulin (Lys lies on B28 site, and Pro on B29 site). Furthermore, it is preferable that, prior to mixing with the soluble analog portion, the insulin-NPH crystal is held for 2 days or longer so as to age and stabilize the crystal. This formulation becomes minimum in the equilibrium exchange expected between the solid phase and the soluble phase, and is stable over a long period.
In the preferred embodiment, a hand-held computer (2) prepares and monitors a goal-oriented weight, nutrition and exercice control program. Visual (5) and audio prompts (140) tell users when to eat and exercise, and provide suggestions for what to eat. The compurter (2) assists the user in setting safe goals for desired weight loss and the time required to achieve the loss. The user follows menu and exercice programs suggested by the computer. The computer records and analyzes the user&#39;s food consumption, exercice and weight loss programs (800). Finally, the computer displays feedback information (1300, 1400) regarding the user&#39;s progress towards achieving the desired weight.
Finely-divided inorganic materials are rendered water-repellent by exposure to the vapour of one or more organo-silicon halides, preferably a methyl silicon halide mixture containing an average of 1 to 3 methyl groups per silicon atom, particularly azeotropic mixtures of trimethyl-chlorosilane and silicon tetrachloride.  The materials may be fillers or pigments for paper, paints, lacquers, face powders or masking creams, e.g., oxides of lead, iron, titanium or zinc, carbonates of calcium and lead, calcium and barium sulphates, aluminium and magnesium silicate, cadmium chromate, zinc sulphide, clays.  Alkyl, aryl, alkaryl or aralkyl silicon halides may be used. In an example, &#34;Catalpo&#34; (Registered Trade Mark) clay thus treated, pasted with a water miscible liquid, e.g., acetone or alcohol, is beaten with wood pulp in water and the product made into paper.  The process improves compatibility, flow, covering power, fluffiness and thixotropy.  Specifications 572,740 and 575,696, [both in Group VIII], are referred to.ALSO:Finely divided inorganic materials are rendered water-repellent by exposure to the vapour of one or more organo silicon halides, preferably a methyl silicon halide mixture containing an average of 1 to 3 methyl groups per silicon atom, particularly azeotropic mixtures of trimethyl chlorsilane and silicon tetrachloride.  The materials may be fillers or pigments for moulded products, paints, paper, &amp;c.  Alkyl, aryl, alkaryl or aralkyl silicon halides may be used.  A series of inorganic oxides and salts are specified.  In an example &#34;Catalpo&#34; (Registered Trade Mark) clay, thus treated, pasted with a water miscible liquid, e.g., acetone or alcohol, is beaten with wood-pulp in water and the product made into paper. The process improves compatibility, flow, covering power, fluffiness and thixotropy.  Specifications 572,740 and 575,696, [both in Group VIII], are referred to.ALSO:Finely - divided inorganic materials are rendered water-repellent by exposure to the vapour of one or more organo silicon halides, preferably a methyl silicon halide mixture containing an average of 1 to 3 methyl groups per silicon atom, particularly azeotropic mixtures of trimethyl chlorsilane and silicon tetrachloride.  The materials may be fillers or pigments for paints, lacquers, face powders or masking creams, e.g. oxides of lead, iron, titanium or zinc, carbonates of calcium and lead, calcium and barium sulphates, aluminium and magnesium silicate, cadmium chromate, zinc sulphide, clays.  Alkyl, aryl, alkaryl or aralkyl silicon halides may be used.  In an example, &#34;Catalpo&#34; (Registered Trade Mark) clay, thus treated and pasted with a water-miscible liquid, e.g. acetone or alcohol, is beaten with wood pulp in water and the product made into paper.  The process improves compatibility, flow, covering power and thixotropy. Specifications 572,740 and 575,696, [both in Group VIII], are referred to.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a modified recombinant virus of improved safety and to provide a method for producing such recombinant virus.  &lt;P&gt;SOLUTION: A recombinant virus which is a modified recombinant virus which has improved safety because its toxicity is attenuated by the inactivation of the gene function encoded by the virus is produced. The gene function is nonessential and is associated with toxicity. As the virus, a poxvirus is advantageous, and it is especially vacciniavirus or avipoxvirus. The modified recombinant virus may contain in its non-essential region of the virus genome a foreign DNA sequence which codes for immunodeficiency virus-derived antigen, epitope and/or CTL epitope, such as HIV1gag (+pro)(IIIB), gp120(MN)(+transmembrane), nef(BRU)CTL, pol(IIIB)CTL, ELDKWA, or LDKW epitope, or the like.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
FIELD: chemistry; biochemistry. ^ SUBSTANCE: invention relates to biotechnology and the DNA version related to adult hypolactasia. The substance of invention includes a nucleic acid molecule containing the 5&#39;-end part of the intestinal digestive lactase-phlorizin hydrolase (LPH) gene which participates or serves as an indicator of adult hypolactasia. The said nucleic acid molecule is selected from a group consisting of: (a) nucleic acid molecules having the SEQ ID N0:1 sequence or containing it, where the SEQ ID NO:1 sequence and (b) nucleic acid molecules having the SEQ ID NO:2 sequence or containing it, (c) nucleic acid molecules consisting of at least 20 nucleotides whose complementary strand is hybridised in strict conditions with the nucleic acid molecule at point (a) or (b), where the said polynucleotide/or nucleic acid molecule contains a cytosine residue in a position corresponding to position -13910 in the 5&#39;-direction from the LPH gene; and (d) nucleic acid molecules consisting of at least 20 nucleotides whose complementary strand is hybridised in strict conditions with the nucleic acid molecule at point (a) or (b), where the said polynucleotide/nucleic acid molecule contains a guanine residue in a position corresponding to position -22018 in the 5&#39;-direction from the LPH gene. ^ EFFECT: design of a method of testing presence or predisposition to adult hypolactasia, which is based on SNP analysis, contained in the said nucleic acid molecule. ^ 65 cl, 7 ex, 8 tbl, 9 dwg
&lt;P&gt;PROBLEM TO BE SOLVED: To display cautionary information in a patient worklist so that it can be easily viewed.  &lt;P&gt;SOLUTION: An apparatus displaying a patient worklist (202) is configured to store patient information including cautionary information (304) and scheduled medical procedures in a memory and further configured to display the patient information on a display screen in a worklist of patient listings (206) for individual patients. The displayed patient information includes scheduled medical procedures for each patient and a visual cautionary indication in a consistent position relative to each patient in the worklist for whom cautionary information is stored. The apparatus is also configured to open a preview pane (302) on the display screen entirely within the viewing area of the display screen when the visual cautionary indication is selected by the pointing device. The preview pane contains cautionary details associated with the corresponding patient for the selected visual cautionary indication.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A urological medical device having a retrieval string is provided. The retrieval string has a proximal end connected the device and an opposed distal end. In a first embodiment, the retrieval string is configured in an initial confined form which, following a period of deployment in a patient&#39;s bladder, changes to an unconfined form in which the distal end of the retrieval string is extendible into the urethra to enable extraction of the device from bladder by pulling the retrieval string. The device may include a bioerodible component which permits the retrieval string to take the unconfined form following degradation of the bioerodible component in vivo. In another embodiment, the retrieval string includes a ferromagnetic material, which can be magnetically captured to facilitate removal of the device from the bladder. The ferromagnetic retrieval string may be buoyant in urine.
&lt;P&gt;PROBLEM TO BE SOLVED: To identify and use a molecule associated with pain.  &lt;P&gt;SOLUTION: This gene sequence which responds to a pain model, is isolated, upregulated in a mammalian spinal cord and identified. This recombinant vector contains the gene sequence. This host cell contains the vector. This nonhuman mammal in which the gene sequence is transduced, deleted or downregulated is obtained. This isolated polypeptide contains an amino acid sequence having at least 90% identity to an amino acid sequence encoded by the gene sequence. An isolated antibody, etc., bonded to the isolated polypeptide is used in screening of a compound for treating or diagnosing pain. Namely, in the screening of the compound for treating or diagnosing pain, a sequence to be upregulated in diabetes induced by streptozocin and chronic constriction injury (CCI) to the nerve reaching the spinal cord is used.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
Compress for eye treatment comprises a support of fibrous material, e.g. a sheet of cellulosic material or non-woven fibrous material, impregnated with a soln. contg. &gt;=1 active substance for local application to the eyes. The compress is wrapped to seal it from air and humidity by several superimposed layers comprising at least one Al sheet sepd. by two sheets of heat-weldable plastics e.g. cellophane, polyethylene and/or PVC. The plastics sheet in contact with the support is inert to the active substances. The plastics sheets are welded along their edges.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a drug delivery vehicle for osteoinductive proteins, that is biocompatible, readily resorbable, and not detrimental to drug activity.  &lt;P&gt;SOLUTION: The problem is solved by providing a composition for treating a mammal having bone defect. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. A method of using the composition and a method of using the osteogenic composition to treat osteoporotic and/or osteopenic bone are also disclosed. A composition for treating the mammal having bone defect, the composition comprising an osteogenetic protein as a bioactive factor, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent is also provided.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
1292768 Benzylimidazolidinones F HOFFMANN-LA ROCHE &amp; CO AG 19 April 1971 [24 Feb 1970] 22437/71 Heading C2C Novel compounds I in which R 1 is -OCH 3 and R 2 is -OC 2 H 5 or R 1 is ethoxy, isopropoxy or butoxy and R 2 is methoxy, are prepared by (a) treating a compound II with alkaline soln.; (b) reacting a compound III with phosgene; (c) treating a compound IV with alcoholic alkali at elevated temperature or (d) reacting a compound V wherein one of R 1 &lt;SP&gt;1&lt;/SP&gt; and R 2 &lt;SP&gt;1&lt;/SP&gt; is OH and the other is as R 1 or R 2 in Formula I with an appropriate alkylating agent. Compounds II are prepared by hydrogenating compounds VI to give compounds VII, reacting compounds VII with hydrazine to give compounds VIII, reacting the hydrazides VIII with nitrous acid by a modified Curtius reaction to give compound IX and hydrogenating these to give the compounds II Compounds III are prepared by acid hydrolysis of compounds II. Compounds IV are prepared by reacting compounds III with chloroethyl carbonate. Compounds V are prepared similarly to compounds II with an additional cyclization step. 3 - Butoxy - 4 - methoxy - benzaldehyde is prepared by reaction of an isovanillin sodium salt with butyl iodide. Pharmaceutical compositions for oral or parenteral administration as cardiovascular agents comprise a compound I together with suitable carriers.
[GB1292768A]
A system selects a user profile based on biometric information. A wearable device is provided with one or more sensors that detect or measure user biometric information selected from of at least one of, a user&#39;s activities, behaviors and habit information, and a user&#39;s health. The wearable device includes circuitry that provides at least identification of the wearable device, a communication system, and a pathway system. A telemetry system is in communication with the wearable device. The telemetry system includes a database of user profiles. The telemetry system uses one or more processors to compare received biometric information from the wearable device, perform a comparison, and determine a user profile stored in a database. The telemetry system selects records of user biometric data of one or more users.
Novel treatments are disclosed for increasing circulating coronary blood flow. These treatments are useful for individuals who are expected to otherwise exhibit symptoms of reduced coronary circulation. Such individuals include those having coronary artery disease, angina, particularly unstable angina and Prinzmetal&#39;s angina, and coronary vasospasm. In accordance with the disclosed methods, coronary vasodilation is accomplished through the administration of effective amounts of ibuprofen and/or flurbiprofen. At the indicated dosages, thromboxane synthesis is effectively inhibited without inhibiting prostacyclin synthesis. Flurbiprofen administration additionally results in thromboxane antagonism.
PURPOSE: Vectors which transfer a gene into an animal cell have many drawbacks and limited applications. An improved viral vector transfers a gene into an animal cell not involving immune response, and replicates stably. CONSTITUTION: Provided are stably episomally replicating vectors, comprising at least one scaffold/matrix attached region (S/MAR) and at least one viral or eukaryotic origin of replication (ORI), cells comprising these, processes for their preparation, and their use, in particular as a medicament or diagnostic. Scaffold/matrix attached region (S/MAR) from 5&#39; region of human interferon beta gene in pTZ-E20 is isolated and cloned into pGFP-C1 to prepare a plasmid which is named pEPI-1. pEPI-1 is electroporated into CHO cell and correct clone is selected. Restriction analysis of isolated DNA and Southern blotting reveal that random integration of vector into chromosome does not happen. Subculture of the selected clones in G418 free medium for 100 generation shows that the vector is stable in CHO cell and keeps kanamycin resistance. Human keratinocyte cell line, HaCat, is transfected with pEPI-1 and correct clone is isolated. After culture for 4 weeks, stable clones are selected and examined the stability of DNA by Southern blotting and PCR. The vector is replicated independently with chromosome and amplified well in the human cell.
In various embodiments, a new, robust fluorometric cell-free biochemical assay that measures HDL redox activity (HRA) is provided. In certain embodiments the assay is based on the oxidation of the fluorochrome AMPLEX® RED in the presence of HRP. HRA correlated with previously validated cell-based (r=0.47, p&lt;0.001) and cell-free assays (r=0.46, p&lt;0.001). HRA measurement identified samples with dysfunctional HDL in established animal models of atherosclerosis and Human Immunodeficiency Virus (HIV) patients. Using an immunoaffinity method for capturing HDL the utility of this novel assay for measuring HRA in a high throughput format was demonstrated. HRA measurements correlated significantly with measures of cardiovascular disease such as carotid intima media thickness (r=0.35, p&lt;0.01) and subendocardial viability ratio (r=-0.21, p=0.05) and physiological parameters such as metabolic and anthropometric parameters (p&lt;0.05). This new fluorometric method that offers a reproducible and rapid means for determining HDL function/quality that is suitable for high throughput implementation.
The present invention discloses use of mitoxantrone in preparing a medicament for preventing or treating acute graft-versus-host disease (aGvHD). How to prevent and treat aGvHD is a great problem puzzling the hematology. The number of donor T cells, the age of the patient, and the like are important factors causing aGvHD. Various aGvHD treatments are present, but none thoroughly cures aGvHD. There&#39;s thus an urgent need for new targeted therapies for aGvHD to solve the problem. Disclosed is a novel function of mitoxantrone – to prevent the development of acute graft versus host disease, which provides a more effective treatment strategy and idea for new treatments of acute graft-versus-host disease.
The invention comprises compounds of formula &lt;FORM:1042197/C2/1&gt; wherein Ph is an o-phenylene group optionally substituted by one or more halogen atoms or alkyl, alkoxy, methylenedioxy or trifluoromethyl groups, Y is a substituted or unsubstituted amino group, R1 is a hydrogen atom or an alkyl or hydroxyalkyl group, and R11 is a hydrogen atom or an alkyl, aryl or aralkyl group, acid addition salts thereof, and their preparation by (a) reduction of a compound of formula &lt;FORM:1042197/C2/2&gt; with in one exemplified case simultaneous reduction of a carboxylic ester group in R1 to form a -CH2OH group, (b) reduction of a compound of formula &lt;FORM:1042197/C2/3&gt; (c) reaction of a compound of formula &lt;FORM:1042197/C2/4&gt; wherein X1 is a reactive esterified hydroxyl group, with ammonia or an amine YH, (d) reacting a compound of formula &lt;FORM:1042197/C2/5&gt; with ammonia, hydroxylamine, or an amine YH, with simultaneous or subsequent reduction of the Schiff&#39;s base formed, and (e) alkylation of a product by reaction with a reactive ester of an alkanol, or with formaldehyde and formic acid, or by acylation to the corresponding amide followed by reduction. 1-N-Furfurylcarbonyl-benzocyclobutene is prepared by reaction of the corresponding carboxylic acid with thionyl chloride, and reaction of the acid chloride thus formed with furfurylamine. 1-Acetal-benzocyclobutene is prepared by treatment of 1-cyano-benzocyclobutene with methyl magnesium iodide, followed by hydrolysis.  1 - Cyano - 1 - (b  - carbethoxyethyl) - benzocyclobutene is prepared by reaction of 1-cyanobenzocyclobutene with ethyl acrylate in the presence of trimethylbenzyl ammonium chloride.  1-Cyano-5-methoxy-benzocyclobutene and 1-cyano-4,5-methylenedioxy-benzocyclobutene are prepared by reaction of 3-bromo-4-methoxybenzaldehyde or 6-bromo-piperonal with malonic acid to give the corresponding o-bromocinnamic acid derivative; hydrogenating this to give the corresponding o-bromo-hydrocinnamic acid derivative, converting this to the corresponding o-bromo-acid chloride by reaction with thionyl chloride, reacting this with ammonia to give the corresponding b -o-bromo-phenyl-propionamide, reacting this with p-toluene-sulphonyl chloride to give the corresponding b -o-bromophenyl-propionitrile and cyclizing this in the presence of potassium amide.  The compounds of the invention have analgesic activity and may be used in pharmaceutical or veterinary compositions in combination with a carrier, for example in forms suitable for oral or parenteral administration such as tablets, capsules, dragees, solutions, suspensions or emulsions.  They may also be used in animal foodstuffs.  Reference has been directed by the Comptroller to Specification 1,001,070.
The invention provides a way for peoples&#39; health to be monitored as they walk down a hallway or through a door frame by tracking their temperatures and by the individuals periodically stopping to give blood samples. An individual&#39;s average temperature and the fluctuations to that temperature can state a lot about their health. Keeping track of this information could potentially allow illnesses to be detected earlier. Through cloud-based software, this information is sent to doctors to later use when determining the progression of an illness of a patient or just to monitor the patient. There would be a monitor and speakers available for the user to be able to interface with the system to access their personal health history and if they are a parent, have access to their children&#39;s information.  Facial recognition would provide a quick way to allow the system to store information about the individual&#39;s health.
PROBLEM TO BE SOLVED: To provide a method for treating infection by a microbial pathogen in a subject by modulating antimicrobial immune response in the subject.SOLUTION: The method of the invention comprises a step of administering an effective amount of antimicrobial polypeptide (AMP) to a subject, where the AMP is IL-22. In one aspect, the infection is a microbial disorder. In one aspect, the microbial disorder is Inflammatory Bowel Disease (IBD). In one aspect, the microbial disorder is Crohn&#39;s disease or ulcerative colitis (UC). In one aspect, the microbial pathogen is a bacteria. In one aspect, the bacteria is gram-negative. In one aspect, the bacteria is gram-positive. In one aspect, the bacteria is attaching or effacing (A/E) bacteria.
Solutions of anthelmintic medicines suitable for administration in an aqueous liquid are prepared by dissolving a halogenated aliphatic hydrocarbon, e.g. carbon tetrachloride in a salt of a basic derivative of a higher fatty acid.  Substances mentioned as suitable are the organic acid salts of diethylamino-ethoxyoleylanilide, substances of the formulae &lt;FORM:0429498/VI/1&gt; &lt;FORM:0429498/VI/2&gt; and of the amidine resulting from the condensation of stearic acid iminoethyl ether hydrochloride and ethylene diamine hydrate. Specifications 308,218, 317,325, and 339,359, [all in Class 2 (iii)], are referred to.  The Specification as open to inspection under Sect. 91 contains references to the use of the condensation products of oleic or stearic acid with a -diethylamino b -hydroxypropylamine or a -diethylamino b -hydroxy-g -phenylamino propane and of compounds described in Specifications 346,387 and 357,250.  This subject-matter does not appear in the Specification as accepted.
A method for making synthetic oligonucleotides which bind to target sequences in a duplex DNA forming colinear triplexes by binding to the major groove. The method includes scanning genomic duplex DNA and identifying nucleotide target sequences of greater than about 20 nucleotides having either about at least 65% purine bases or about at least 65% pyrimidine bases; and synthesizing synthetic oligonucleotides complementary to identified target sequences. The synthetic oligonucleotides have a G when the complementary location in the DNA duplex has a GC base pair and have a T when the complementary location in the DNA duplex has an AT base pair. The synthetic oligonucleotides are oriented 5&#39; to 3&#39; and bind parallel or 3&#39; to 5&#39; and bind anti-parallel to the about at least 65% purine strand. Also described are synthetic oligonucleotides made by the above methods. The oligonucleotides can be altered by modifying and/or changing the bases, adding linkers and modifying groups to the 5&#39; and/or 3&#39; termini, and changing the backbone. These synthetic oligonucleotides bind to duplex DNA to form triplexes. This process alters the functioning of the genes which are bound. This process can be used to inhibit cell growth, alter protein ratios, treat diseases including cancer and permanently alter the DNA.